SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+1.95%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.65B
AUM Growth
+$1.65B
(+3.8%)
Cap. Flow
+$95.2M
Cap. Flow
% of AUM
5.78%
Top 10 Holdings %
Top 10 Hldgs %
61.91%
Holding
77
New
11
Increased
17
Reduced
15
Closed
10
Top Buys
| 1 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$85.8M |
| 2 |
Vera Therapeutics
VERA
|
$38.7M |
| 3 |
Biogen
BIIB
|
$38.3M |
| 4 |
Sarepta Therapeutics
SRPT
|
$23.2M |
| 5 |
Heron Therapeutics
HRTX
|
$22.8M |
Top Sells
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$42.1M |
| 2 |
Eli Lilly
LLY
|
$33.7M |
| 3 |
Merus
MRUS
|
$27.4M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$22.5M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$14M |
Sector Composition
| 1 | Healthcare | 98.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $352M | 20.29% | 3,100,560 | – | – |
|
|
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $223M | 12.83% | 1,952,441 | – | – |
|
|
JBIO
3
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $85.8M | 4.95% | +3,758,686 | New | +$85.8M |
|
4
Y-mAbs Therapeutics
YMAB
$388M
| $74.2M | 4.27% | 2,194,278 | – | – |
|
5
Ascendis Pharma
ASND
$11.8B
| $68.7M | 3.96% | 521,923 | – | – |
|
6
AstraZeneca
AZN
$248B
| $57.5M | 3.31% | 959,632 -76,100 | -7% | -$4.56M |
|
7
Bolt Biotherapeutics
BOLT
$9.85M
| $42.6M | 2.45% | 2,754,437 | – | – |
|
8
United Therapeutics
UTHR
$13.8B
| $38.8M | 2.23% | 216,085 +1,031 | +0.5% | +$185K |
|
|
9
Vera Therapeutics
VERA
$1.38B
| $38.7M | 2.23% | +2,914,776 | New | +$38.7M |
|
|
10
Biogen
BIIB
$19.4B
| $38.3M | 2.21% | +110,600 | New | +$38.3M |
|
|
INZY
11
DELISTED
Inozyme Pharma
INZY
| $34.6M | 1.99% | 2,028,308 | – | – |
|
|
GRTX
12
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $30.3M | 1.75% | 3,083,712 | – | – |
|
|
XLRN
13
DELISTED
Acceleron Pharma Inc.
XLRN
| $29.3M | 1.69% | 233,638 +55,100 | +31% | +$6.91M |
|
14
Align Technology
ALGN
$10.3B
| $28.8M | 1.66% | 47,093 +1,593 | +4% | +$973K |
|
15
PTC Therapeutics
PTCT
$3.92B
| $24.6M | 1.42% | 581,940 +115,100 | +25% | +$4.87M |
|
16
Insmed
INSM
$28.8B
| $24M | 1.38% | 844,169 +225,219 | +36% | +$6.41M |
|
|
17
Sarepta Therapeutics
SRPT
$1.78B
| $23.2M | 1.34% | +298,500 | New | +$23.2M |
|
|
18
Heron Therapeutics
HRTX
$207M
| $22.8M | 1.31% | +1,467,675 | New | +$22.8M |
|
|
CMPI
19
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $21.5M | 1.24% | 3,606,707 | – | – |
|
20
NextCure
NXTC
$13.5M
| $21.5M | 1.24% | 2,671,856 | – | – |
|
21
Protagonist Therapeutics
PTGX
$3.67B
| $20.2M | 1.16% | 449,082 -205,818 | -31% | -$9.24M |
|
22
Neurocrine Biosciences
NBIX
$13.8B
| $19.8M | 1.14% | +203,200 | New | +$19.8M |
|
23
Exelixis
EXEL
$10.1B
| $19.7M | 1.13% | 1,079,681 +240,500 | +29% | +$4.38M |
|
|
AKUS
24
DELISTED
Akouos, Inc. Common Stock
AKUS
| $19M | 1.1% | 1,515,074 | – | – |
|
25
Insulet
PODD
$23.9B
| $18.8M | 1.08% | 68,500 +51,000 | +291% | +$14M |
|